Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

McKesson
McKinsey
Baxter
Harvard Business School
AstraZeneca
Boehringer Ingelheim

Last Updated: May 27, 2022

Investigational Drug Information for GDC-0917


✉ Email this page to a colleague

« Back to Dashboard

What is the drug development status for GDC-0917?

GDC-0917 is an investigational drug.

There have been 184 clinical trials for GDC-0917. The most recent clinical trial was a Phase 3 trial, which was initiated on October 27th 2016.

The most common disease conditions in clinical trials are Breast Neoplasms, Carcinoma, and Lymphoma. The leading clinical trial sponsors are Genentech, Inc., National Cancer Institute (NCI), and Hoffmann-La Roche.

There are twelve US patents protecting this investigational drug and one hundred and ninety-five international patents.

Recent Clinical Trials for GDC-0917
TitleSponsorPhase
Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung CancerNational Cancer Institute (NCI)Phase 1
Testing the Safety and Efficacy of the Addition of A New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Etoposide and Cisplatin) for Adult and Pediatric Patients (12-17 Years) With NUT CarcinomaNational Cancer Institute (NCI)Phase 1/Phase 2
Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSLKazia Therapeutics LimitedPhase 2

See all GDC-0917 clinical trials

Clinical Trial Summary for GDC-0917

Top disease conditions for GDC-0917
Top clinical trial sponsors for GDC-0917

See all GDC-0917 clinical trials

US Patents for GDC-0917

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
GDC-0917 See Plans and Pricing Use of inhibitor of apoptosis protein (IAP) antagonists in HIV therapy SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE (La Jolla, CA) SALK INSTITUTE FOR BIOLOGICAL STUDIES (La Jolla, CA) See Plans and Pricing
GDC-0917 See Plans and Pricing SMC combination therapy for the treatment of cancer Children's Hospital of Eastern Ontario Research Institute Inc. (Ottawa, ON, CA) See Plans and Pricing
GDC-0917 See Plans and Pricing Benzolactam compounds as protein kinase inhibitors OTSUKA PHARMACEUTICAL CO., LTD. (Tokyo, JP) See Plans and Pricing
GDC-0917 See Plans and Pricing Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activity ASTEX THERAPEUTICS LIMITED (Cambridge, GB) CANCER RESEARCH TECHNOLOGY LIMITED (London, GB) See Plans and Pricing
GDC-0917 See Plans and Pricing Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activity ASTEX THERAPEUTICS LIMITED (Cambridge, GB) CANCER RESEARCH TECHNOLOGY LIMITED (London, GB) See Plans and Pricing
GDC-0917 See Plans and Pricing Modulators of estrogen receptor proteolysis and associated methods of use ARVINAS OPERATIONS, INC. (New Haven, CT) See Plans and Pricing
GDC-0917 See Plans and Pricing Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders Arvinas Operations, Inc. (New Haven, CT) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for GDC-0917

Drugname Country Document Number Estimated Expiration Related US Patent
GDC-0917 Canada CA2950911 2034-06-04 See Plans and Pricing
GDC-0917 European Patent Office EP3151920 2034-06-04 See Plans and Pricing
GDC-0917 Japan JP2017522273 2034-06-04 See Plans and Pricing
GDC-0917 Japan JP2020125302 2034-06-04 See Plans and Pricing
GDC-0917 Japan JP6768522 2034-06-04 See Plans and Pricing
GDC-0917 World Intellectual Property Organization (WIPO) WO2015187998 2034-06-04 See Plans and Pricing
GDC-0917 Canada CA2974651 2034-01-24 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
McKinsey
Baxter
Harvard Business School
AstraZeneca
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.